Label Woes For GSK’s Jesduvroq Dampen US Anemic Kidney Disease Approval

 
• By Ayisha Sharma

The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.  

Doctor in white coat holding up tablet displaying kidneys
There Are 810,000 People With End-Stage Renal Disease In The US • Source: Shutterstock

More from New Products

More from Scrip